Scientists: The First COVID Shots May Be Less Than Optimal
October 29, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Liz Szabo, Kaiser Health News, and JoNel Aleccia, Kaiser Health News The White House and many Americans have pinned their hopes for defeating the COVID-19 pandemic on a vaccine being developed at “warp speed.” But some scientific experts warn they’re all expecting too much, too soon. “Everyone thinks COVID-19 will go away with a vaccine,” said William Haseltine, Ph.D., chair and president of Access Health International, a foundation that advocates for affordable care. Ongoing clinical trials are primarily designed to show

Read More

Study: Millennials Expect to Spend More on Meds
October 16, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Sharon Klahr Coey The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in mid-March to find out what people were thinking about the then-emerging pandemic. The finding? A lot of concerned consumers. But Mindshare also found that the more consumers worry about their health, the more they plan to spend on medications, Alexis Fragale, Mindshare’s director of consumer insights, said. Overall,

Read More

New FDA Vaccine Rules Could Nix Pre-Election COVID-19 Shot
October 8, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Eric Sagonowsky A weeks-long feud between the White House and FDA over COVID-19 vaccine guidelines took another turn Tuesday as the agency released vaccine recommendations despite efforts by the White House to keep them under wraps. The FDA advises two months of monitoring after patients’ final doses, which could thwart President Donald Trump’s desire for a shot before the election. As COVID-19 vaccines move closer to potential reviews at the FDA, experts with the agency last month prepared to publish a

Read More